Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling

Neuropharmacology

Volumn 54, Issue 1, 2008, Pages 36-44

  Daigle, Tanya L ^a   Kearn, Christopher S ^a   Mackie, Ken ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

arrestin; Cannabinoids; Desensitization; Internalization; MAP kinase; Phosphorylation

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BETA ARRESTIN; CANNABINOID 1 RECEPTOR; CONCANAVALIN A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RIMONABANT; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; CYCLOHEXANOL DERIVATIVE; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RETINA S ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; CELL LINE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN TRANSPORT; TIME;

ARRESTINS; CELL LINE, TRANSFORMED; CYCLOHEXANOLS; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 37349043924     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.06.005     Document Type: Article

References (40)

1. Andersson H., D'Antona A.M., Kendall D.A., Von Heijne G., and Chin C.N. Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol. Pharmacol. 64 (2003) 570-577
2. Arttamangkul S., Torrecilla M., Kobayashi K., Okano H., and Williams J.T. Separation of mu-opioid receptor desensitization and internalization: endogenous receptors in primary neuronal cultures. J. Neurosci. 26 (2006) 4118-4125
3. Bass C.E., and Martin B.R. Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 60 (2000) 113-119
4. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., and Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312 Pt. 2 (1995) 637-641
5. + exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways. FEBS Lett. 449 (1999) 61-65
6. Breivogel C.S., Scates S.M., Beletskaya I.O., Lowery O.B., Aceto M.D., and Martin B.R. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur. J. Pharmacol. 459 (2003) 139-150
7. Brown S.M., Wager-Miller J., and Mackie K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim. Biophys. Acta 1576 (2002) 255-264
8. Campbell R.E., Tour O., Palmer A.E., Steinbach P.A., Baird G.S., Zacharias D.A., and Tsien R.Y. A monomeric red fluorescent protein. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 7877-7882
9. Claing A., Laporte S.A., Caron M.G., and Lefkowitz R.J. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog. Neurobiol. 66 (2002) 61-79
10. Coutts A.A., Anavi-Goffer S., Ross R.A., MacEwan D.J., Mackie K., Pertwee R.G., and Irving A.J. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J. Neurosci. 21 (2001) 2425-2433
11. Daaka Y., Luttrell L.M., Ahn S., Della Rocca G.J., Ferguson S.S., Caron M.G., and Lefkowitz R.J. Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J. Biol. Chem. 273 (1998) 685-688
12. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., Trzaskos J., Caboche J., and Girault J.A. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. 23 (2003) 2371-2382
13. Dewire S.M., Ahn S., Lefkowitz R.J., and Shenoy S.K. beta-Arrestins and cell signaling. Annu. Rev. Physiol. 69 (2007) 483-510
14. Gainetdinov R.R., Premont R.T., Bohn L.M., Lefkowitz R.J., and Caron M.G. Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 27 (2004) 107-144
15. Gonzalez S., Cebeira M., and Fernanadez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol. Biochem. Behav. 81 (2005) 300-318
16. Glass M., and Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17 (1997) 5327-5333
17. Hoffman A.F., Oz M., Caulder T., and Lupica C.R. Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J. Neurosci. 23 (2003) 4815-4820
18. Howlett A.C., and Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26 (1984) 532-538
19. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
20. Hsieh C., Brown S., Derleth C., and Mackie K. Internalization and recycling of the CB1 cannabinoid receptor. J. Neurochem. 73 (1999) 493-501
21. Huang J., Sun Y., and Huang X.Y. Distinct roles for Src tyrosine kinase in beta2-adrenergic receptor signaling to MAPK and in receptor internalization. J. Biol. Chem. 279 (2004) 21637-21642
22. Jimenez-Sainz M.C., Fast B., Mayor Jr. F., and Aragay A.M. Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. Mol. Pharmacol. 64 (2003) 773-782
23. Jin W., Brown S., Roche J.P., Hsieh C., Celver J.P., Kovoor A., Chavkin C., and Mackie K. Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J. Neurosci. 19 (1999) 3773-3780
24. Kearn C.S., Blake-Palmer K., Daniel E., Mackie K., and Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?. Mol. Pharmacol. 67 (2005) 1697-1704
25. Kouznetsova M., Kelley B., Shen M., and Thayer S.A. Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Mol. Pharmacol. 61 (2002) 477-485
26. Kramer H.K., and Simon E.J. mu and delta-opioid receptor agonists induce mitogen-activated protein kinase (MAPK) activation in the absence of receptor internalization. Neuropharmacology 39 (2000) 1707-1719
27. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 308 (2005) 512-517
28. Leterrier C., Bonnard D., Carrel D., Rossier J., and Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J. Biol. Chem. 279 (2004) 36013-36021
29. Li J.G., Luo L.Y., Krupnick J.G., Benovic J.L., and Liu-Chen L.Y. U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation. J. Biol. Chem. 274 (1999) 12087-12094
30. Mackie K., and Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 3825-3829
31. Mackie K., Lai Y., Westenbroek R., and Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15 (1995) 6552-6561
32. Martin B.R., Sim-Selley L.J., and Selley D.E. Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol. Sci. 25 (2004) 325-330
33. Mato S., Chevaleyre V., Robbe D., Pazos A., Castillo P.E., and Manzoni O.J. A single in vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat. Neurosci. 7 (2004) 585-586
34. McDonald N.A., Henstridge C.M., Connolly C.N., and Irving A.J. An essential role for constitutive endocytosis, but not activity, in the axonal targeting of the CB1 cannabinoid receptor. Mol. Pharmacol. 71 (2007) 976-984
35. Rinaldi-Carmona M., Le Duigou A., Oustric D., Barth F., Bouaboula M., Carayon P., Casellas P., and Le Fur G. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J. Pharmacol. Exp. Ther. 287 (1998) 1038-1047
36. Roche J.P., Bounds S., Brown S., and Mackie K. A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol. Pharmacol. 56 (1999) 611-618
37. Rubino T., Forlani G., Vigano D., Zippel R., and Parolaro D. Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol. Cell. Neurosci. 25 (2004) 355-362
38. Shenoy, S.K., Lefkowitz, R.J., 2005. Seven-transmembrane receptor signaling through beta-arrestin. Sci STKE 2005, cm10.
39. Sim-Selley L.J. Regulation of cannabinoids CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol. 15 (2003) 91-119
40. Valjent E., Pages C., Rogard M., Besson M.J., Maldonado R., and Caboche J. Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur. J. Neurosci. 14 (2001) 342-352